ARID1A and ovarian cancer: Loss of ARID1A expression also leads to chemotherapy resistance in a variety of tumors, including lung cancer (Huang et al., 2024), ovarian cancer (Duska et al., 2023) and pancreatic cancer (Li et al., 2022).